Endothelial-monocyte-activating polypeptide II.
Endothelial-monocyte-activating polypeptide II (EMAP II) was initially identified as a product of murine methylcholanthrene A-induced fibrosarcoma cells. The deduced mRNA sequence indicates that EMAP II is synthesised as a 34 kDa precursor molecule (proEMAP) and enzymatically cleaved to produce a biologically active 22 kDa mature polypeptide, which has been isolated and characterised. It modulates a range of properties of endothelial cells, monocytes, and neutrophils in vitro, and induces an acute inflammatory reaction and tumour regression in vivo. Recent evidence suggests that EMAP II can induce apoptosis in endothelial cells, and as such may act in an anti-angiogenic role. The question arises whether EMAP II is primarily a pro-inflammatory cytokine or a novel mediator of programmed cell death.
Tas
M P
MP
CRC Department of Clinical Oncology, University of Nottingham, City Hospital, U.K.
Murray
J C
JC
D000818:Animals; D017209:Apoptosis; D016207:Cytokines; D004727:Endothelium; D006801:Humans; D007249:Inflammation; D009000:Monocytes; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins
D016207:Cytokines; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins; C077219:small inducible cytokine subfamily E, member 1